In recent years, global healthcare has transformed, with Contract Development and Manufacturing Organizations (CDMOs) emerging as essential players in this evolution. CDMOs now play a critical role in the timely distribution of life-saving treatments to patients worldwide, bridging the gap between scientific innovation and real-world impact. These specialized companies have evolved beyond traditional roles, now supporting the entire journey of biopharmaceutical development — from research to formulation, manufacturing, and finishing. Among these, mAbxience has positioned itself at the forefront, contributing innovative, adaptable solutions to meet the growing complexity of modern medicine.
Meeting the growing demand for flexibility and innovation
As the healthcare sector navigates new challenges and opportunities, CDMOs like mAbxience have adapted to meet changing demands. By offering end-to-end services, mAbxience serves as a trusted partner for biopharmaceutical companies across every stage of their projects. Remarkably, we established a partnership in just three months as AstraZeneca’s chosen partner to manufacture their COVID-19 vaccine in South America and delivered over 200 million doses, highlighting mAbxience’s commitment to flexibility and operational excellence in meeting urgent healthcare needs and ensuring critical treatments reach patients timely and efficiently.
With substantial investments in specialized infrastructure and advanced manufacturing processes, mAbxience has created a CDMO model with a platform capable of adapting to unique customer needs, offering essential flexibility for today’s dynamic healthcare environment. Our extensive use of single-use systems significantly reduces operational costs (which translates into COGS reduction for customers), minimizes the risk of cross-contamination, allows faster change-overs, and enhances scalability — all crucial benefits in a time- and cost-sensitive industry.
Consolidating expertise and building trust
For over 14 years, mAbxience has established a robust portfolio of biologics, with three commercialized products approved by multiple regulatory agencies worldwide, and six new biosimilars currently in development. This impressive track record is a testament to our competitive in-house R&D capabilities, strong internal intellectual property (IP) and strategic regulatory department, which has demonstrated experience in navigating complex approval processes. mAbxience offers this wealth of knowledge and expertise to our CDMO partners, enabling them to accelerate time to market and fostering lasting relationships rooted in trust and proven performance.
Enabling the future of healthcare together
mAbxience’s commitment to continuous improvement, innovation, agility and operational excellence is reshaping how therapies are developed and made accessible to patients on a global scale. Through our ongoing contributions, we are not just supporting biopharmaceutical companies but actively shaping the future of global healthcare by ensuring that life-saving treatments reach patients who need them most, faster and more reliably than ever before.
For further detailed information about our CDMO services, please visit mabxience.com/cdmo-services or contact us at contact@mabxience.com to discover how we can assist with your manufacturing and development projects.
